EMERYVILLE, Calif.–(BUSINESS WIRE)—- $OABI #OABI–OmniAb, Inc. (NASDAQ: OABI) announces the launch of its new OmniUltra™ platform, the industry’s first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. OmniUltra is a versatile in vivo discovery platform that extends beyond traditional antibody modalities into the peptide space, enabling multiple therapeutic appli
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
